Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 1,668,357 shares, a growth of 56.3% from the August 15th total of 1,067,589 shares. Based on an average daily trading volume, of 35,561,049 shares, the days-to-cover ratio is currently 0.0 days. Currently, 4.5% of the company’s shares are short sold.

Werewolf Therapeutics Price Performance

NASDAQ:HOWL traded up $0.04 on Thursday, hitting $0.96. 571,048 shares of the company’s stock were exchanged, compared to its average volume of 2,793,299. The firm has a 50-day moving average price of $0.61 and a 200-day moving average price of $0.62. Werewolf Therapeutics has a 52 week low of $0.27 and a 52 week high of $2.38. The company has a market cap of $46.80 million, a P/E ratio of -1.27 and a beta of 0.51.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Friday, July 31st. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.36. The company had revenue of $21.00 million for the quarter, compared to analyst estimates of $21.00 million. On average, research analysts expect that Werewolf Therapeutics will post -0.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Luke Evnin sold 107,429 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total value of $33,302.99. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at $37,000. Squarepoint Ops LLC bought a new position in shares of Werewolf Therapeutics in the second quarter valued at about $37,000. Finally, Bank of America Corp DE acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth about $112,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

HOWL has been the subject of several research analyst reports. Wall Street Zen upgraded shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Weiss Ratings upgraded shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company uses its proprietary INDUKINE platform to design conditionally activated cytokines, which are intended to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues.

Werewolf’s pipeline has included WTX-124, an investigational interleukin-2 therapy designed to promote the expansion and activation of immune cells in tumors, and WTX-330, an investigational interleukin-12 therapy intended to activate both innate and adaptive immune responses.